Also found in: Dictionary, Wikipedia.


an antispasmodic agent used in treatment of bladder hyperactivity.


Detrol, Detrol LA, Detrusitol (UK), Detrusitol XL (UK)

Pharmacologic class: Anticholinergic

Therapeutic class: Urinary tract antispasmodic

Pregnancy risk category C


Competitively antagonizes muscarinic receptors, inhibiting bladder contractions and reducing urinary frequency


Capsules (extended-release): 2 mg, 4 mg

Tablets: 1 mg, 2 mg

Indications and dosages

Overactive bladder

Adults: 2 mg (immediate-release) P.O. b.i.d.; may decrease to 1 mg P.O. b.i.d. depending on response and tolerance. Or 4 mg (extended-release) P.O. daily; may decrease to 2 mg P.O. daily, depending on response.

Dosage adjustment

• Hepatic impairment or disease

• Renal impairment

• Concurrent use of potent CYP3A4 inhibitors


• Hypersensitivity to drug, its components, or to fesoterodine fumarate extended-release tablets

• Urinary or gastric retention

• Uncontrolled angle-closure glaucoma


Use cautiously in:

• GI obstruction, significant bladder outflow obstruction, controlled angle-closure glaucoma, significant hepatic impairment, renal impairment

• pregnant or breastfeeding patients

• children (safety not established).


• Give with food to increase bioavailability.

Adverse reactions

CNS: headache, dizziness, vertigo, drowsiness, paresthesia, fatigue

CV: chest pain

EENT: vision abnormalities, xerophthalmia, pharyngitis

GI: diarrhea, constipation, abdominal pain, dyspepsia, dry mouth

GU: dysuria, urinary retention or frequency, urinary tract infection

Musculoskeletal: joint pain

Skin: dry skin

Other: weight gain, flulike symptoms, infection, anaphylaxis, angioedema


Drug-drug. Clarithromycin, erythromycin, itraconazole, ketoconazole, miconazole: inhibited metabolism and increased effects of tolterodine

Drug-food. Any food: increased drug bioavailability

Patient monitoring

Monitor patient for anaphylaxis and angioedema with first or subsequent doses. If difficulty breathing, upper airway obstruction, or fall in blood pressure occurs, discontinue drug and promptly provide appropriate treatment.

Monitor patient for signs and symptoms of anticholinergic CNS effects, particularly after beginning treatment or increasing dosage. Consider dosage reduction or drug discontinuation if symptoms occur.

• Monitor bladder function.

• Assess blood pressure and stay alert for chest pain.

• Monitor neurologic status. Report paresthesia or visual impairment.

Patient teaching

• Tell patient to take with food.

• If patient takes extended-release form, instruct him not to chew or crush it.

Instruct patient how to recognize and immediately report signs and symptoms of anaphylaxis or angioedema.

• Caution patient not to drive or operate heavy machinery until drug's effects are known.

• Advise patient to use sugarless gum or hard candy to relieve dry mouth.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.


/tol·ter·o·dine/ (tol-ter´ah-dēn) an antispasmodic used in the treatment of bladder hyperactivity.


a muscarinic receptor antagonist.
indications It is used to treat overactive bladder (frequency and urgency). It controls bladder incontinence by controlling contractions.
contraindications Factors that prohibit its use include known hypersensitivity, uncontrolled narrow-angle glaucoma, urinary retention, and gastric retention.
adverse effects Adverse effects include paresthesia, fatigue, headache, chest pain, hypertension, vision abnormalities, xerophthalmia, abdominal pain, constipation, dry mouth, dyspepsia, dysuria, urinary retention, urinary frequency, urinary tract infection, rash, pruritus, bronchitis, cough, pharyngitis, and upper respiratory infection. Common side effects include anxiety, dizziness, nausea, vomiting, and anorexia.


Detrol® Urology An agent used to manage overactive bladder Contraindications Urinary retention, gastric retention, narrow-angle glaucoma
References in periodicals archive ?
17 compared the adverse reactions of patients who were treated by either solifenacin or tolterodine.
However, in the EG group, this natural benign prostatic hyperplasia process was postponed by the long-term, continued use of tolterodine, an unselective M-receptor blocker.
propiverine, solifenacin, tolterodine, and trospium) in OAB by Chapple
has released tolterodine tartrate ER capsules in strengths of 2 mg and 4 mg.
A pooled safety analysis of the three 12-week phase III studies yielded similar overall incidences of adverse effects in mirabegron (25-100 mg/day), placebo, and tolterodine ER 4 mg/day groups.
Tolterodine Tartrate ER Capsules are reportedly the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Safety and tolerability of mirabegron versus tolterodine for OAB
tolterodine; dry mouth and constipation were more likely with oxybutynin than with tolterodine.
Tolterodine titrate first became available in 2001 as 1 or 2 mg tablets, and 2 or 4 mg sustained-release tablets.
Tolterodine is a muscarinic receptor antagonist generally used in the treatment of incontinence and overactive urinary bladder.
Anthistamines Diphenhydramine (Benadryl); hydroxyzine (Atarax); cetirizine (Zyrtec); loratadine (Claricin) Sleep medications Diphenhydramine (Tylenol PM) Nausea medications Prochlorperazine (Compazine) Antidepressants Amitriptyline (Elavil); paroxetine (Paxil); fluoxetine (Prozac); mirtazapine (Remeron); trazodone Incontinence drugs Tolterodine (Detrol); oxybutynin (Ditropan) Irritable bowel Dicyclomine (Bentyl) medications Vertigo/seasickness Scopolamine patch (Transderm Scop); drugs meclizine (Antivert); dimenhydrinate (Dramamine) Muscle relaxants Baclofen Antacids Cimetidine (Tagamet); ranitidine (Zantac) Antidiarrheals Loperamide (Imodium)